Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Haemonetics (HAE) over the last 11 years, with Q4 2025 value amounting to -$2.1 million.

  • Haemonetics' Deferred Taxes rose 1468.76% to -$2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.6 million, marking a year-over-year increase of 8175.8%. This contributed to the annual value of -$5.2 million for FY2025, which is 5272.22% up from last year.
  • Per Haemonetics' latest filing, its Deferred Taxes stood at -$2.1 million for Q4 2025, which was up 1468.76% from -$725000.0 recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Deferred Taxes peaked at $3.4 million during Q1 2025, and registered a low of -$15.9 million during Q2 2021.
  • Over the past 5 years, Haemonetics' median Deferred Taxes value was -$2.2 million (recorded in 2024), while the average stood at -$2.2 million.
  • Data for Haemonetics' Deferred Taxes shows a peak YoY increase of 59319.73% (in 2021) and a maximum YoY decrease of 61971.96% (in 2021) over the last 5 years.
  • Haemonetics' Deferred Taxes (Quarter) stood at -$121000.0 in 2021, then soared by 2590.91% to $3.0 million in 2022, then tumbled by 207.66% to -$3.2 million in 2023, then grew by 25.52% to -$2.4 million in 2024, then increased by 14.69% to -$2.1 million in 2025.
  • Its Deferred Taxes stands at -$2.1 million for Q4 2025, versus -$725000.0 for Q3 2025 and -$3.2 million for Q2 2025.